Market Overview

UPDATE: Canaccord Genuity Initiates Coverage on MiMedx Group on Potential of New Segment


In a report published Friday, Canaccord Genuity analyst William J. Plovanic initiated coverage on MiMedx Group (NASDAQ: MDXG) with a Buy rating and $6.00 price target.

In the report, Canaccord Genuity noted, “By our estimates, the dermal substitute segment of the advanced wound care market generated ~$354M of revenues in 2012, growing ~23% per year since 2009. MiMedx utilizes distinct distribution channels for its three revenue reporting segments: Wound Care, Surgical & Sports Medicine, and Other/OEM. We believe the increasing number of reps in the direct channel on the commercial side for wound care, combined with improved coverage, will drive top-line growth in 2013 and beyond. AWC Direct reps are expected to increase to ~140 by YE15 from ~49 in Q2/13.”

MiMedx Group closed on Thursday at $4.54.

Latest Ratings for MDXG

Feb 2018Lake StreetDowngradesBuyHold
Feb 2018NeedhamDowngradesStrong BuyHold
May 2017First AnalysisDowngradesEqual-WeightUnderweight

View More Analyst Ratings for MDXG
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity William J. PlovanicAnalyst Color Initiation Analyst Ratings


Related Articles (MDXG)

View Comments and Join the Discussion!

Latest Ratings

FNKODA DavidsonMaintains9.5
REALB of A SecuritiesMaintains21.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at